October 4, 2022
Taiho Pharmaceutical said on October 3 that it has earned the US FDA’s accelerated approval for its fibroblast growth factor receptor (FGFR) inhibitor futibatinib for the treatment of certain patients with advanced bile duct cancer. The drug, previously known as...read more